α2-Antiplasmin is associated with macrophage activation and fibrin deposition in a macrophage activation syndrome

Yosuke Kanno1, Kinomi Toyama1, Haruna Shibata1

  • 1Department of Molecular Pathology, Faculty of Pharmaceutical Science, Doshisha Women's College of Liberal Arts, Kodo Kyo-tanabe, Kyoto, Japan.

Insights

Alpha2-antiplasmin (α2AP) exacerbates macrophage activation syndrome (MAS) by promoting macrophage migration and fibrin deposition. Blocking α2AP in a mouse model reduced MAS severity, suggesting α2AP as a potential therapeutic target.

Area of Science:

  • Immunology
  • Hematology
  • Pathophysiology

Background:

  • Macrophage activation syndrome (MAS) is a severe, life-threatening hyperinflammatory condition.
  • MAS involves excessive macrophage activation, leading to cytopenia, multi-organ dysfunction, and coagulopathy.

Purpose of the Study:

  • To investigate the role of alpha2-antiplasmin (α2AP) in the progression of MAS.
  • To explore α2AP's influence on macrophage activation and related inflammatory pathways.

Main Methods:

  • Utilized a fulminant MAS mouse model induced by toll-like receptor-9 agonist (CpG) and D-(+)-galactosamine hydrochloride (DG).
  • Assessed the effects of α2AP deficiency and blockade by neutralizing antibodies on MAS progression.
  • Examined α2AP's impact on interferon-γ (IFN-γ)-induced macrophage migration and tissue factor production.

Main Results:

  • α2AP deficiency attenuated macrophage accumulation, liver injury, and fibrin deposition in MAS model mice.
  • α2AP enhanced IFN-γ-induced macrophage migration and tissue factor production.
  • Fibrin induced macrophage activation and tumor necrosis factor-α production, which was modulated by α2AP.

Conclusions:

  • α2AP plays a significant role in MAS progression by regulating IFN-γ-induced responses.
  • α2AP is associated with increased macrophage activation and fibrin deposition in MAS.
  • Targeting α2AP may offer a therapeutic strategy for managing MAS.